01

IDO1 Inhibitor Fails to Amplify T-Cell Response to Melanoma Vaccine

A clinical trial reports that combining an IDO1 inhibitor with a melanoma vaccine did not increase tumor-fighting T cells, undermining a key immunooncology hypothesis.